Reviewed by Michael Gill, B. Sc.
Image of Medical College of Wisconsin in Milwaukee, United States.
Phase-Based Progress Estimates
1
Effectiveness
1
Safety

3-Hour Groupfor Obesity

18+
All Sexes
More than 84 million - or 1 out of every 3 U.S. adults - have prediabetes, a condition that if not treated often leads to type 2 diabetes within five years. Average medical expenditures among diabetics are about 2.3 times higher than expenditures for people without diabetes. Physical inactivity and elevated body mass index (BMI) are major risk factors for the disease. Sedentary behavior is becoming increasingly prevalent with the growth of a 'work from home' culture, most recently driven by the COVID-19 pandemic. Cross-sectional epidemiologic data report significant associations between high amounts of sedentary (sitting) time and prevalent cardiovascular disease and diabetes. In our pilot study of 15 subjects with sedentary office jobs, 6 months of sit-stand desk use resulted in a 23% improvement in insulin resistance, most substantial in those who decreased daily sitting by over 90 minutes/day. Additional improvements in vascular endothelial function and triglyceride levels were seen without any change in exercise activity, step counts, or body weight. These findings not only corroborate epidemiologic findings on this topic but suggest causality and warrant a randomized control trial. The investigators hypothesize that adult subjects at-risk for diabetes will improve insulin sensitivity, metabolic and vascular (endothelial) health with a sit-stand desk intervention at work (whether in the office or at home), in the context of a randomized, controlled trial. The investigators will randomize 198 sedentary office workers with a BMI≥25 at risk for type 2 diabetes mellitus in a 1:1:1 ratio of three groups: (a) sit-stand desk intervention targeting 2 hours standing per day; (b) sit-stand desk intervention targeting 3 hours standing per day; or (c) control arm over 6 months. The block randomization design will allow for important dose-response analyses. The investigators will objectively quantify standing time, sedentary time, sedentary bouts, daily steps, and exercise activity times using a compact and re-usable accelerometer that adheres to the subject's thigh. This will provide objective assessments of activity levels and sedentary times for 7 full days each at baseline, 3 and 6 months. The device is equipped with an inclinometer to classify posture (sitting verses standing).
Waitlist Available
Has No Placebo
Medical College of Wisconsin
Image of True You Weight Loss in Cary, United States.
Phase-Based Progress Estimates
1
Effectiveness
1
Safety

Gastric Fundic Ablation Plus Endoscopic Sleeve Gastroplastyfor Obesity

18+
All Sexes
The purpose of this research is to investigate the effects of fundic ablation (FA) on circulating plasma ghrelin, satiation, and total body weight loss, as well as the incidence of adverse events. This procedure will be carried out with the HybridAPC (ERBE Elektromedizin GmbH, Tübingen, Germany). The HybridAPC instrument creates an electric current to deliver a safe amount of thermal injury to a portion of the stomach known as the gastric fundus. This thermal injury will target a hormone called ghrelin which is the only known hormone linked to increasing appetite, calorie intake, and weight gain. This procedure is designed to target the bodily effects of appetite control and gastric sensory and motor functions which cause the feeling of fullness and satiation. The fundic mucosal ablation is not typically done prior to the endoscopic sleeve gastroplasty procedure. When fundic mucosal ablation is sequentially paired with endoscopic sleeve gastroplasty (ESG), this combined investigational approach may lead to decreased fasting ghrelin levels, improved satiation, and greater total body weight loss than traditional ESG. This study will help determine if the combined impact of FA with ESG should be made available to patients as part of a comprehensive weight loss strategy.
Phase 1 & 2
Recruiting
True You Weight LossChristopher E McGowan, MD, MSCR
25 Obesity Clinical Trials Near Me
Top Hospitals for Obesity Clinical Trials
Image of University of Alabama at Birmingham in Alabama.
University of Alabama at Birmingham
Birmingham
5Active Trials
36All Time Trials for Obesity
2000First Obesity Trial
Top Cities for Obesity Clinical Trials
Obesity Clinical Trials by Phase of Trial
Phase < 1 Obesity Clinical Trials
3Active Obesity Clinical Trials
3Number of Unique Treatments
3Number of Active Locations
Deferred group - pioglitazoneCircadian Study ProtocolNeuropeptide Y
Obesity Clinical Trials by Age Group
< 18 Obesity Clinical Trials
12Active Obesity Clinical Trials
Meal KitsWhole milkPrevention PlusModerately carbohydrate-restricted dietLactobacillus PlantarumInterpersonal Psychotherapy (IPT)Mindfulness-Based InterventionPatient navigation